PaxMedica Inc., a US-based biopharmaceutical company, announced on Friday that it has received approval from the South African Health Products Regulatory Agency (SAHPRA) for its clinical trial application to study the impacts of PAX-101 (suramin intravenous (IV) infusions) in patients with Long COVID-19 Syndrome, also known as post-acute sequelae of SARS-CoV-2 infection.
The study is named PAX-LCS-101 and it will be a Phase 1B, prospective, randomised, placebo-controlled, double-blind, multiple-dose study. It is likely to start enrolling subjects in the first quarter of 2022 after receiving South African National Ethics Committee approval. This clinical trial is planned to study the safety and tolerability, efficacy, and PK of two doses of suramin (5mg/kg and 10mg/kg) in adults, 18 years and older, with LCS.
The product is also in phase two investigations for Autism Spectrum Disorder (ASD). The firm is also producing PAX-102, a proprietary intranasal formulation of suramin, for ASD and other neurologic disorders.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer